Goldman Sachs Group Inc F Star Therapeutics, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding FSTX
# of Institutions
3Shares Held
44.7KCall Options Held
0Put Options Held
0About F-star Therapeutics, Inc.
- Ticker FSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,584,700
- Description
- F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck c...